Photodynamic therapy (PDT) is a medical technique for the treatment of cancer. It is based on the use of non-toxic molecules, called photosensitizers (PSs), that become toxic when irradiated with light and produce reactive oxygen specious (ROS) such as singlet oxygen (1O2). This light-induced toxicity is rather selective since the physician only targets a specific area of the body, leading to minimal side effects. Yet, a strategy to improve further the selectivity of this medical technique is to confine the delivery of the PS to cancer cells only instead of spreading it randomly throughout the body prior to light irradiation. To address this problem, we present here novel sulfonamide-based monopodal and dipodal ruthenium and osmium polypyridyl complexes capable of targeting carbonic anhydrases (CAs) that are a major target in cancer therapy. CAs are overexpressed in the membrane or cytoplasm of various cancer cells. We therefore anticipated that the accumulation of our complexes in or outside the cell prior to irradiation would improve the selectivity of the PDT treatment. We show that our complexes have a high affinity for CAs, accumulate in cancer cells overexpressing CA cells and importantly kill cancer cells under both normoxic and hypoxic conditions upon irradiation at 540 nm. More importantly, Os(II) compounds still exhibit some phototoxicity under 740 nm irradiation under normoxic conditions. To our knowledge, this is the first description of ruthenium/osmium-based PDT PSs that are CA inhibitors for the selective treatment of cancers.
22 September 2023 in Chemistry – A European Journal
Light‐activated treatments, such as photodynamic therapy (PDT), provide temporal and spatial control over a specific cytotoxic response by exploiting toxicity differences between irradiated and dark conditions. In this work, a novel strategy for developing near infrared (NIR)‐activatable Ru(II) polypyridyl‐based photosensitizers (PSs) was successfully developed through the incorporation of symmetric heptamethine cyanine dyes in the metal complex via a phenanthrimidazole ligand. Owing to their strong absorption in the NIR region, the PSs could be efficiently photoactivated with highly penetrating NIR light (770 nm), leading to high photocytotoxicities towards several cancer cell lines under both normoxic and hypoxic conditions. Notably, our lead PS (Ru‐Cyn‐1), which accumulated in the mitochondria, exhibited a good photocytotoxic activity under challenging low‐oxygen concentration (2 % O2) upon NIR light irradiation conditions (770 nm), owing to a combination of type I and II PDT mechanisms. The fact that the PS Protoporphyrin IX (PpIX), the metabolite of the clinically approved 5‐ALA PS, was found inactive under the same challenging conditions positions Ru‐Cyn‐1 complex as a promising PDT agent for the treatment of deep‐seated hypoxic tumours.
In this work, we aimed at photocaging the well‐known anticancer agents dasatinib, ceritinib, gemcitabine, and combretastatin A4 with red‐light activatable 4,4‐difluoro‐4‐bora‐3a,4a‐diaza‐s‐indacene (BODIPY)‐based cages using a carbonate/carbamate linking strategy. Due to the synthetic challenges discussed in this article, we only obtained two target compounds, namely two caged ceritinib compounds. The latter were characterized in‐depth by nuclear magnetic resonance spectroscopy (NMR, 1H, COSY, 13C), high‐resolution mass spectrometry (HRMS), infrared (IR) spectroscopy, and their purity was evaluated by elemental analysis. Their photophysical characteristics were also measured including absorption and emission spectra, quantum yields, and lifetimes. Analysis of the products after irradiation of the compounds allowed us to make assumptions about the possible mechanism of the phototransformations. Moreover, we conducted biological studies to determine the phototoxicity indexes of A549 cancer cells. While the two compounds were found to be non‐toxic, the BODIPY precursors themselves were found to be highly toxic upon irradiation with phototoxicity indexes up to 1400.
Photocages are photosensitive molecules that can release specific compounds, usually of biological relevance (e.g., drugs, cellular messengers, etc.), under light irradiation. Along with these compounds, the photocages themselves are putative release byproducts. The (photo-)cytotoxicity of them is hardly known and scarcely studied. To explore these compounds, we synthesized the known BODIPY derivatives commonly used as photocages, i.e., WinterGreen and WinterRed. We investigated in depth their photophysical properties in organic solvents and phosphate buffer. The formation of aggregates by the compounds was analyzed by dynamic light scattering (DLS) and spectral methods, which demonstrated their J-aggregate nature. All compounds exhibited significant phototoxicity in biological assays upon light irradiation at two wavelengths (510 and 645 nm), corresponding to their absorption maxima, in both cancerous (A549) and non-cancerous (RPE-1) cell lines. Investigations into the reactive oxygen species (ROS) generation in organic solutions and intracellularly suggested that the observed phototoxicity might arise via a type I photodynamic therapy (PDT) mechanism. These findings highlight the need for greater scrutiny of photocages themselves in biological studies. Far from being inert carriers, they may exert substantial biological effects, and in some cases, their activity could even surpass that of the released therapeutic agent.
The development of “non-natural” chemical reactions inside living organisms is an expanding field of research. In this area, metal-based catalysis has been particularly scrutinised. However, most examples of catalysts developed so far are based on expensive and rare heavy metals such as ruthenium, iridium or palladium. For this reason, the development of catalysis in cells or in vivo with more accessible first-row metals is of great interest and could significantly increase the catalogue of reactions applicable in these complex environments. Herein, we demonstrate that encapsulating copper(I) N-heterocyclic carbene (NHC) catalysts inside the cavity of modified cyclodextrins, renders these notoriously toxic complexes harmless towards CT26 cells at high concentrations. Nevertheless, the catalytic activity of cyclodextrin (CD)–encapsulated NHC–copper complexes is preserved, allowing the deprotection of pinacol boronate ester groups outside and inside living cells to release phenol-based fluorophores. In cells, the production of fluorophore in the presence of CD–NHC–copper catalysts outperforms that induced by the cellular machinery alone and endogeneous ROS.
11 May 2026 in Angewandte Chemie International Edition
Immunogenic cell death (ICD), which converts tumor cells into their own vaccine, plays a pivotal role in the development of novel anticancer therapies. Here, a small series of osmium(II) polypyridyl complexes was synthesized, and their biological activity in the dark and upon light irradiation against various cancer cell lines was studied. The compound Os2 (bearing two 4,7‐diphenyl‐1,10‐phenanthrolines and one substituted bipyridine ligand) was discovered to be the most effective photosensitizer (PS) for photodynamic therapy (PDT) of this series through the photogeneration of 1 O 2 and •OH. In addition, Os2 was found to exhibit promising toxicity upon deep‐red irradiation under both normoxia and hypoxia. These observations indicate that this PS is working through a mixture of Type‐I and Type‐II mechanisms. More interestingly, upon 740 nm irradiation, Os2 can stimulate a strong ICD response on CT26 and MCA205 cells both in vitro and in vivo. A comprehensive immune analysis showed that mice vaccinated with Os2 ‐treated CT26‐luc cells boosted the systemic specific adaptive immune responses, including the activation of CD8 + T cells and reprogramming of macrophages, leading to effective inhibition of tumor growth. Os2 is, to the best of our knowledge, the first photoactive osmium‐based complex inducing ICD.